Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Introduction
Neuroendocrine tumors (NETs) of the gastroenteropancreatic (GEP) system are a rare and heterogeneous group of tumors. At the time of diagnosis, the majority of NETs have already metastasized, accounting for a rather low 5-year survival rate of less than 50% [1], [2]. As currently available antiproliferative strategies against GEP-NETs (biotherapy, chemotherapy) have modest efficacy, novel therapeutic approaches are urgently needed.
The PI(3)K–Akt–mTOR- and the Ras–Raf–MEK-Erk1/2 pathway are crucial for the regulation of cell survival and proliferation. Growth factors initiate both signaling pathways by activating receptor tyrosine kinases (RTKs), which in turn leads to the activation of PI(3)K and its downstream targets Akt and mTOR on one hand and Ras and its downstream targets Raf, MEK and ERK1/2 on the other hand [3]. Akt, as well as Erk1/2 promote cell survival and proliferation by either directly or indirectly downregulating proapoptotic and cell cycle-inhibitory proteins such as Bim, Bad, p27 and p21. Conversely, Akt and Erk1/2 upregulate antiapoptotic and cell cycle promoting proteins such as Bcl-2, Bcl-XL, c-Myc and cyclin D1 [4]. One major target of Akt is the mTORC1, which is composed of mTOR, regulatory-associated protein of mTOR (raptor) and mLST8. Two well-characterized mTORC1 substrates are eukaryotic translation initiation factor 4E (eIF4E)-binding protein (4EBP1) and p70 ribosomal S6 kinase (p70S6K), both regulating transcription and translation initiation of critical growth genes. Moreover, p70S6K is part of a powerful negative feedback loop on PI(3)K–Akt signaling [5]. The second mTOR-containing complex, mTORC2, consists of mTOR, rapamycin-insensitive companion of mTOR (rictor), Sin1, mLST8 and protein associated with Rictor (protor). It is less understood than mTORC1 but recent work indicates that it is part of the PI(3)K–Akt pathway as it mediates Akt phosphorylation on Ser473 which is required for full Akt activity [6], [7].
There is accumulating evidence that the PI(3)K-Akt-mTOR- and the Ras–Raf–MEK–ERK1/2 pathway closely cooperate in the transduction of survival signals. For instance, Ras and PI(3)K can directly activate each other and Akt has been found to inhibit Raf [8]. In addition, a recent study by Carracedo et al. revealed a p70S6K-mediated negative feedback loop on Raf-MEK-Erk signaling [9].
The PI(3)K–Akt–mTOR- and the Ras–Raf–MEK–ERK1/2 pathways are among the major signaling networks that have been implicated in human cancer including NETs. Indeed, a recent study found that 76% of all examined NET samples were positive for activated Akt and 96% were positive for activated ERK1/2 [10]. Molecular analysis of NETs suggests that in addition to mutations in certain tumor suppressor genes (e.g. PTEN, B-Raf), autocrine growth factor loops contribute to hyperactive PI(3)K–Akt–mTOR- and Ras–Raf–MEK–ERK1/2 signaling. For instance, abnormal high or constitutive expression of IGF-I and IGF-IR-TK has been detected in the majority of NETs and considerably contributes to neuroendocrine secretion and tumor cell growth [11], [12]. Not surprisingly, those insights have prompted several approaches of specifically targeting tyrosine and serine/threonine kinases along the P(3)K–Akt–mTOR- and Ras–Raf–MEK–ERK1/2 pathway. Among the huge number of selective small-molecule inhibitors that have been recently introduced for cancer therapy, several have already been tested in NETs. For instance, the mTOR inhibitor RAD001 and the Raf inhibitor sorafenib have both demonstrated potent antitumor activity in vitro and have recently been evaluated in patients with advanced NET disease [13], [14], [15], [16], [17]. Out of 60 patients receiving RAD001 orally 5 or 10 mg daily and depot octreotide intramusculary every 28 days, partial response (PR) or stable disease (SD) were observed in 22% and 70% of patients, respectively. In contrast, tumor response to sorafenib was modest with PR and SD rates of 10% and 50%, respectively.
Here, we comparatively test the antitumor potential of novel small-molecule-inhibitors specifically targeting mTOR (RAD001), mTOR/PI(3)K (NVP-BEZ235) and Raf (Raf265) in three NET cell lines of pancreatic, midgut and bronchial origin. Our results suggest the existence of a novel compensatory feedback mechanism between PI(3)K–Akt–mTOR- and Ras–Raf–MEK–ERK1/2 survival signaling and provide a rationale for dual targeting of these pathways in NET disease.
Section snippets
Reagents
RAD001, NVP-BEZ235, RAF265 and NVP-AEW541 were kindly provided from Novartis Pharma (Basel, Switzerland).
Cell culture
Human pancreatic neuroendocrine BON1 tumor cells were kindly provided by R. Göke (Marburg, Germany) and cultured in DMEM/F12 (1:1) medium (Gibco/Invitrogen, Karlsruhe, Germany). Human midgut carcinoid GOT1 cells were kindly provided by Ola Nilsson (Göteborg, Sweden). Human bronchopulmonary neuroendocrine NCI-H727 tumor cells were purchased by ATCC (Manassas, VA, USA). GOT1 and NCI-H727 cells
Treatment with RAD001, NVP-BEZ235 and Raf265 dose- and time-dependently decreases NET cell viability
The so-called addiction hypothesis provides a rationale for molecular-targeted therapy [20]. Human pancreatic BON1 tumor cells were previously shown to exhibit constitutive Akt phosphorylation due to an autocrine IGF-I loop [11]. Western Blot analysis revealed similar high levels of basal Akt phosphorylation in human midgut carcinoid (GOT1)- and bronchus carcinoid (NCI-H727) cells (data not shown). In contrast, BON1- and NCI-H727 cells exhibit poor basal Erk phosphorylation, while GOT1 cells
Discussion
The PI(3)K–Akt–mTOR pathway and the Ras–Raf–MEK–Erk pathway are prototypic survival pathways that have been implicated in tumorigenesis of many cancers including NETs. The “oncogene addiction hypothesis” proposes that tumor cells become dependent on oncogenic pathways and develop hypersensitivity to inhibition of the key oncogenic actor, thus providing a rationale for targeted therapy approaches [20]. In this study, we comparatively investigate the antitumor potential of novel small-molecule
Conflicts of interest
No potential conflicts of interest were disclosed.
Acknowledgments
C.J. Auernhammer received a restricted research grant from Novartis Oncology Germany. S. Brand was supported by grants from the DFG (BR 1912/5-1), the Else Kröner-Fresenius-Stiftung (Else Kröner Memorial Stipendium 2005, P50/05/EKMS05/62), the Ludwig-Demling Grant 2007 from DCCV e.V. and the Excellence Initiative of the Ludwig-Maximilians-University Munich (Investment Funds 2008).
References (36)
- et al.
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3–L1 adipocytes
J. Biol. Chem.
(2005) - et al.
Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells
Biochem. Biophys. Res. Commun.
(2006) - et al.
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
J. Immunol. Methods.
(1991) - et al.
Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling
J. Biol. Chem.
(2004) - et al.
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis
Cell
(2005) - et al.
The diagnosis and medical management of advanced neuroendocrine tumors
Endocr. Rev.
(2004) Natural history of neuroendocrine enteropancreatic tumors
Digestion
(2000)Cotargeting survival signaling pathways in cancer
J. Clin. Invest.
(2008)- et al.
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Leukemia
(2008) - et al.
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
Cancer Res.
(2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Science
The PTEN-PI3K pathway: of feedbacks and cross-talks
Oncogene
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
J. Clin. Invest.
Epidermal growth factor receptor expression and activation in neuroendocrine tumours
J. Neuroendocrinol.
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells
Cancer Res.
PI(3)K–Akt–mTOR pathway as a potential therapeutic target in neuroendocrine tumors
Exp. Rev. Endocrinol. Metabol.
The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Neuroendocrinology
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line
Neuroendocrinology
Cited by (119)
Quenching thirst with poison? Paradoxical effect of anticancer drugs
2023, Pharmacological ResearchTargeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer
2022, Drug Resistance UpdatesTargeting translation regulators improves cancer therapy
2021, GenomicsRelevance of neuroendocrine tumours models assessed by kinomic profiling
2019, Annales d'EndocrinologieLong non-coding RNAs: Functional regulatory players in breast cancer
2019, Non-coding RNA Research
- 1
Both authors contributed equally to this manuscript.